VolitionRx Limited (VNRX) Stock Analysis — Probabli.AI
AI-powered analysis for VNRX (VolitionRx Limited): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $0.14 · Market cap: $22.2M · AI consensus: Bullish
VolitionRx Limited (VNRX) is a high-potential biotech firm focused on developing innovative non-invasive diagnostics for cancer. The firm's nucleosomics technology holds promise, supported by a strong positive sentiment among analysts, a high revenue growth trajectory, and new catalysts such as funding success and trial milestones. Risks remain due to its early-stage commercialization,…
Probabilistic 1-Year Outlook
- Bull 4800% · Neutral 4000% · Bear 1200%
- VolitionRx Limited has demonstrated strong momentum through recent positive trial results and an impressive revenue growth estimate. The market sentiment, reflected in analysts' ratings and their estimates, also leans…
5-Year Outlook
- Bull 6000% · Neutral 3000% · Bear 1000%
SWOT Highlights
- Strength: Innovative nucleosomics technology with promising trial results.
- Strength: High revenue growth potential as evidenced by current estimates.
- Risk: Currently low revenue base leading to operational uncertainty.
- Risk: Early-stage commercialized products with unproven scale.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
5 Wall Street analysts rate VNRX a BUY with a mean price target of $1.67.
Analysis generated Apr 27, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/VNRX.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.